Interim results of phase II study shows survival benefit of THIO in NSCLC

S2302 Pragmatica-Lung reports out as model for faster, leaner, more representative trials

The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad eligibility criteria, and reduced data collection, has quickly answered its primary question, finding that the investigational combination it tested did not significantly extend overall survival compared to standard of care treatments.

Neoadjuvant immunotherapy + chemo regimen significantly improves long-term survival in NSCLC

Adding immunotherapy to chemotherapy before surgery for patients with operable non-small cell lung cancer improved long-term survival overall compared with chemotherapy alone, according to a clinical trial published June 2 in The New England Journal of Medicine and presented at the annual meeting of the American Society of Clinical Oncology.

Poorly functioning blood vessels lead to muscle wasting in cancer, preclinical study finds

A dysfunction in muscle blood vessels could be to blame for the weak muscles and weight loss that most cancer patients experience, according to a new study from University of Illinois Chicago researchers.

OncoHost study offers insights into resistance mechanisms in immunotherapy-treated lung cancer

A recent OncoHost study provides insight in understanding resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer. Through a comprehensive bioinformatic analysis of pretreatment plasma proteomic profiles from 272 NSCLC patients, researchers identified key biological processes associated with resistance and revealed therapeutic targets that could inform future precision treatment strategies.

Drugs & Targets

China’s NMPA approves zanidatamab in China for previously treated, unresectable or metastatic HER2+ biliary tract cancer

The National Medical Products Administration in China approved zanidatamab for the treatment of patients with previously treated, unresectable or metastatic HER2-positive biliary tract cancer.